PBS updates

Keytruda (Pembrolizumab)

pembrolizumab 100 mg/4 mL injection, 4 mL vial · INJECTION · PBS code 15208K

STREAMLINED

What it costs

AU$3632.56 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2026-02-01.
  • • Repeats: 7.
  • • PBS program: IP.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Intermediate or high risk of recurrence clear cell variant renal cell carcinoma (RCC)


Patient must have: (i) pT2 with Grade 4 or sarcomatoid features; or (ii) pT3, with any grade without nodal involvement (N0) or distant metastases (M0); or (iii) pT4, any grade N0 and M0; or (iv) any pT, any grade with nodal involvement and M0; or (v) metastatic disease and has undergone complete resection of primary and metastatic lesions; AND

The treatment must be in addition to complete surgical resection; AND

The treatment must commence within 12 weeks of complete resection; AND

Patient must have a WHO performance status of 1 or less; AND

Patient must not have previously been treated with systemic therapy for this condition, prior to commencing treatment with this drug for this condition; AND

The treatment must be the sole PBS-subsidised anti-cancer therapy for this condition; AND

Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy; AND

Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 7 repeat prescriptions; or

Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd ABN 14 000 173 508

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.